RxDoctor Payments DataLook up a doctor →

Antoine Azar, MD

Allergy & Immunology · Baltimore, MDNPI 1811029242

Payments from drug & device makers

$989,943in general payments, 2019–2025

Across 710 payments — averaging $1394.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • X4 Pharmaceuticals, Inc.$220K
  • Grifols USA, LLC$214K
  • Takeda Pharmaceuticals U.S.A., Inc.$152K
  • Grifols Shared Services North America, Inc.$111K
  • Argenx US, Inc.$66K
  • ADMA Biomanufacturing LLC$61K
  • plus $166K from 20 others
$6,625in research payments, 2019–2025

Across 2 payments — averaging $3312.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$5K
  • Octapharma USA, Inc.$1K

What the payments were for

  • Consulting fees$187,70031%
  • Speaking & faculty fees$329,96554%
  • Travel & lodging$75,28512%
  • Food & beverage$18,5793%
  • Education$2760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$989,943 in reported general payments places this provider in the 95th percentile of 105 allergy & immunology providers in Maryland.

See all allergy & immunology providers in Maryland

Medicare billing

Part B allowed, 2024
$33,123
Medicare patients
152
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XembifyImmune Globulin,gamma(Igg)klhw13$268,027
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$54,745
XhanceFluticasone Propionate13$14,962
Azelastine Hcl21$1,091
Ipratropium Bromide12$693
Montelukast Sodium12$264
Albuterol Sulfate HfaAlbuterol Sulfate11$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCXembify$214,073$268,02713 claims
CSL BehringPrivigen$53,142$54,74512 claims
Optinose US, Inc.Xhance$12,641$14,96213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 allergy & immunology providers in Maryland.

Other allergy & immunology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →